Violin Jonathan's Form 4/A amendment
AmendedViridian Therapeutics, Inc.DEVRDN · filed Feb 7, 2023
- Accession no.
- 0000899243-23-004233
- Filed
- Feb 7, 2023, 6:35 PM ET
- Trade date
- Feb 2, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Feb 7, 2023
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.84M. It was filed 5 days after the trade.
This amendment replaces 0000899243-23-003921 (filed Feb 3, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Violin JonathanCIK 0001730615 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2023 | Common Stock | MOption exerciseAcquired | +50,000 | $0.15 | +$7,500 | 530,905 | Direct | |
| Feb 2, 2023 | Common Stock | SSaleDisposed | −50,000 | $36.80F2 | −$1,840,000 | 480,905 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2023 | Common Stock | MOption exerciseDisposed | −50,000 | $0.00 | $0 | 239,205 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Due to a broker error, the Form 4 filed by the Reporting Person on February 3, 2023 incorrectly reported the source of shares sold on February 2, 2023 pursuant to the Reporting Person's Rule 10b5-1 trading plan. This amendment reflects the exercise of stock options for 50,000 shares of common stock, which were the source of the shares sold.
- F2
This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
The option vested 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.